CHINA RES.PHARMA.GRP O.N. financial statements, including revenue, expenses, and profit
The total revenue of 640 for the last semiannual is 17.41 B EUR, and it's 4.49% higher compared to the previous semiannual. The net income of H2 24 is 100.60 M EUR.